ORIC® Pharmaceuticals To Participate In Upcoming Investor Conferences

(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will be participating in the following investor conferences in February:

• Guggenheim Emerging Outlook: Biotech Summit – Participating in a fireside chat on Thursday, February 12, 2026, at 10:30 a.m. ET. Management will also be participating in one-on-one meetings.
  
• Citi's 2026 Virtual Oncology Leadership Summit – Participating in a fireside chat on Wednesday, February 18, 2026, at 2:30 p.m. ET. Management will also be participating in one-on-one meetings.
  
• Oppenheimer 36 ^th Annual Healthcare Life Sciences – Participating in a fireside chat on Wednesday, February 25, 2026, at 12:00 p.m. ET. Management will also be participating in one-on-one meetings.
  

Webcasts of the fireside chat discussions will be available through the investor section of the company's website at . Replays of the webcasts will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) rinzimetostat (ORIC-944), an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 and PACC mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to , and follow us on X or LinkedIn.

Contact:

Dominic Piscitelli, Chief Financial Officer
...
...

MENAFN05022026004107003653ID1110702866